Medication info

Citamin Tablet 50/1000 mg (Sitagliptin Phosphate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Phosphate›62.04mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
IYON Pharmaceutical Co., Ltd.
Appearance
Red oval film-coated tablet
Packaging
30 tablets/box [10 tablets/PTP x 3]
Approval status
Active

MFDS item code 201603082 · Approved 2016.05.30

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their existing doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral hypoglycemic agents. Any change in treatment for type 2 diabetes may result in changes in glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Ingredients

Manufacturer
IYON Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help blood sugar control when patients with type 2 diabetes combine dietary control and exercise therapy. The components sitagliptin and metformin work together to effectively regulate and improve blood sugar levels. Therefore, it serves as a good therapeutic adjunct for those needing blood sugar management.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this medicine should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy who cannot achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's existing metformin dose. - Patients switching to this medicine from concomitant sitagliptin and metformin therapy may start at their existing doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient's blood glucose level and existing dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with other oral hypoglycemic agents. Any change in treatment for type 2 diabetes may result in changes in glycemic control; caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medicine should be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).

Precautions

This medication contains two components, and there are points to be cautious about for each component. First, one of the components may cause allergic reactions. Severe allergy reactions or skin conditions can occur within three months after administration, so if such symptoms are suspected, it is necessary to stop taking the medication immediately and consult a doctor. Second, this medication can cause pancreatitis, a serious pancreatic disease, so if symptoms such as abdominal pain, nausea, or vomiting occur during treatment, inform a healthcare provider immediately. Third, the other component should not be administered to patients with impaired kidney function, and patients with severe infections, heart failure, or acute myocardial infarction that could affect kidney function should also avoid taking this medication. Fourth, this medication can cause a rare but fatal metabolic disorder called lactic acidosis, so regular kidney and liver function tests should be conducted, and it should be discontinued during dehydration, severe vomiting, or diarrhea. Fifth, during the use of this medication, alcohol consumption should be avoided, and before undergoing sudden surgery or radiological contrast examinations, the healthcare provider should be consulted to temporarily stop taking the medication. Sixth, this medication can cause hypoglycemia, so particularly when taken with insulin or other blood sugar-lowering agents, blood sugar levels should be checked frequently, and if hypoglycemia symptoms appear, immediate action should be taken. Seventh, it is safer for pregnant or potentially pregnant women and breastfeeding women not to take this medication. Finally, the safety and efficacy of this medication have not been established in children, so it should not be used in pediatric patients under 18 years old. It is crucial to conduct regular blood tests and physical examinations during the use of this medication to detect abnormal symptoms early and continuously monitor health status.

Side effects

Hypersensitivity, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory tract infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia with severe and disabling symptoms, blistering resembling pemphigus, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, vitamin B12 deficiency, dermatitis, anorexia, weight loss, dyspnea, unstable angina, dizziness, acute renal failure, decreased appetite, gastrointestinal disturbances, itching

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent the entry of air and moisture, ideally at room temperature between 1 degree and 30 degrees Celsius. Proper storage can help maintain the medication's efficacy.

Appearance and packaging

Appearance

Red oval film-coated tablet

Package unit

30 tablets/box [10 tablets/PTP x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.